Abstract
Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.
Original language | English (US) |
---|---|
Pages (from-to) | e145-e154 |
Journal | Biology of Blood and Marrow Transplantation |
Volume | 25 |
Issue number | 5 |
DOIs | |
State | Published - May 2019 |
Keywords
- Complication
- Eye
- Hematopoietic cell transplantation
- Prevention
- Review
- Treatment
ASJC Scopus subject areas
- Hematology
- Transplantation
Fingerprint
Dive into the research topics of 'Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 5, 05.2019, p. e145-e154.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation
T2 - Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation
AU - Inamoto, Yoshihiro
AU - Petriček, Igor
AU - Burns, Linda
AU - Chhabra, Saurabh
AU - DeFilipp, Zachariah
AU - Hematti, Peiman
AU - Rovó, Alicia
AU - Schears, Raquel
AU - Shah, Ami
AU - Agrawal, Vaibhav
AU - Ahmed, Aisha
AU - Ahmed, Ibrahim
AU - Ali, Asim
AU - Aljurf, Mahmoud
AU - Alkhateeb, Hassan
AU - Beitinjaneh, Amer
AU - Bhatt, Neel
AU - Buchbinder, Dave
AU - Byrne, Michael
AU - Callander, Natalie
AU - Fahnehjelm, Kristina
AU - Farhadfar, Nosha
AU - Gale, Robert Peter
AU - Ganguly, Siddhartha
AU - Hashmi, Shahrukh
AU - Hildebrandt, Gerhard C.
AU - Horn, Erich
AU - Jakubowski, Ann
AU - Kamble, Rammurti T.
AU - Law, Jason
AU - Lee, Catherine
AU - Nathan, Sunita
AU - Penack, Olaf
AU - Pingali, Ravi
AU - Prasad, Pinki
AU - Pulanic, Drazen
AU - Rotz, Seth
AU - Shreenivas, Aditya
AU - Steinberg, Amir
AU - Tabbara, Khalid
AU - Tichelli, André
AU - Wirk, Baldeep
AU - Yared, Jean
AU - Basak, Grzegorz W.
AU - Battiwalla, Minoo
AU - Duarte, Rafael
AU - Savani, Bipin N.
AU - Flowers, Mary E.D.
AU - Shaw, Bronwen E.
AU - Valdés-Sanz, Nuria
N1 - Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institute of Allergy and Infectious Diseases, National Cancer Institute (NCI), and National Heart, Lung, and Blood Institute (NHLBI); Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration; Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, *Amgen, *Amneal Biosciences, *Angiocrine Bioscience, Anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be the Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology; *Celgene, Cerus, *Chimerix, Fred Hutchinson Cancer Research Center, Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Medac, MedImmune, Medical College of Wisconsin, *Mediware, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, National Marrow Donor Program, *Neovii Biotech NA, Novartis Pharmaceuticals, Otsuka Pharmaceutical, the Patient-Centered Outcomes Research Institute, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, *Sunesis Pharmaceuticals, Swedish Orphan Biovitrum, Takeda Oncology, Telomere Diagnostics, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institute of Allergy and Infectious Diseases, National Cancer Institute (NCI) , and National Heart, Lung, and Blood Institute (NHLBI) ; Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI ; Contract HHSH250201200016C with the Health Resources and Services Administration ; Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, *Amgen, *Amneal Biosciences, *Angiocrine Bioscience, Anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be the Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology; *Celgene, Cerus, *Chimerix, Fred Hutchinson Cancer Research Center, Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Medac, MedImmune, Medical College of Wisconsin, *Mediware, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, National Marrow Donor Program, *Neovii Biotech NA, Novartis Pharmaceuticals, Otsuka Pharmaceutical, the Patient-Centered Outcomes Research Institute, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, *Sunesis Pharmaceuticals, Swedish Orphan Biovitrum, Takeda Oncology, Telomere Diagnostics, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. Funding Information: Financial disclosure: The Center for International Blood and Marrow Transplant Research is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Institute of Allergy and Infectious Diseases, National Cancer Institute (NCI), and National Heart, Lung, and Blood Institute (NHLBI); Grant/Cooperative Agreement 4U10HL069294 from the NHLBI and NCI; Contract HHSH250201200016C with the Health Resources and Services Administration; Grants N00014-17-1-2388 and N0014-17-1-2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, *Amgen, *Amneal Biosciences, *Angiocrine Bioscience, Anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara Biotherapeutics, Be the Match Foundation, *bluebird bio, *Bristol Myers Squibb Oncology; *Celgene, Cerus, *Chimerix, Fred Hutchinson Cancer Research Center, Gamida Cell, Gilead Sciences, HistoGenetics, Immucor, *Incyte, Janssen Scientific Affairs, *Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Medac, MedImmune, Medical College of Wisconsin, *Mediware, *Merck & Co, *Mesoblast, MesoScale Diagnostics, Millennium, *Miltenyi Biotec, National Marrow Donor Program, *Neovii Biotech NA, Novartis Pharmaceuticals, Otsuka Pharmaceutical, the Patient-Centered Outcomes Research Institute, *Pfizer, *Pharmacyclics, PIRCHE, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals, St. Baldrick's Foundation, *Sunesis Pharmaceuticals, Swedish Orphan Biovitrum, Takeda Oncology, Telomere Diagnostics, and the University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration, or any other agency of the US Government. *Corporate members. Conflict of interest statement: There are no conflicts of interest to disclose. Authorship statement: Y.I. I.P. and N.S. contributed equally to this work. Publisher Copyright: © 2018 American Society for Blood and Marrow Transplantation
PY - 2019/5
Y1 - 2019/5
N2 - Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.
AB - Non-graft-versus-host disease (GVHD)ocular complications are generally uncommon after hematopoietic cell transplantation (HCT)but can cause prolonged morbidity affecting activities of daily living and quality of life. Here we provide an expert review of non-GVHD ocular complications in a collaboration between transplantation physicians and ophthalmologists through the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Complications discussed in this review include cataracts, glaucoma, ocular infections, ocular involvement with malignancy, ischemic microvascular retinopathy, central retinal vein occlusion, retinal hemorrhage, retinal detachment and ocular toxicities associated with medications. We summarize the incidence, risk factors, screening, prevention, and treatment of individual complications and generate evidence-based recommendations. Baseline ocular evaluation before HCT should be considered in all patients who undergo HCT. Follow-up evaluations should be considered according to clinical signs and symptoms and risk factors. Better preventive strategies and treatments remain to be investigated for individual ocular complications after HCT. Both transplantation physicians and ophthalmologists should be knowledgeable about non-GVHD ocular complications and provide comprehensive collaborative team care.
KW - Complication
KW - Eye
KW - Hematopoietic cell transplantation
KW - Prevention
KW - Review
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85059228103&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059228103&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2018.11.033
DO - 10.1016/j.bbmt.2018.11.033
M3 - Review article
C2 - 30521975
AN - SCOPUS:85059228103
SN - 1083-8791
VL - 25
SP - e145-e154
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 5
ER -